Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Real-world studies of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) have shown worse outcomes in patients with poor Eastern Cooperative Oncology Group Stage Performance Status (ECOG PS). This index measures functional status but does not assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez Galán, Rocío, Prado-Mel, Elena, Alvarez de Sotomayor, Maria, Martin, Laila Abdel-Kader
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953107/
https://www.ncbi.nlm.nih.gov/pubmed/36829469
http://dx.doi.org/10.3390/biology12020191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953107/
https://www.ncbi.nlm.nih.gov/pubmed/36829469
http://dx.doi.org/10.3390/biology12020191

Ejemplares similares